Spiriva Review: COPD-Related Dyspnea Needs Clearer Definition – FDA Cmte.

Chronic obstructive pulmonary disease-related dyspnea endpoints need to be more clearly defined before they can support a labeled indication, FDA's Pulmonary-Allergy Drugs Advisory Committee agreed during its review of Boehringer Ingelheim/Pfizer's Spiriva